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Background: Antiretroviral treatment (ART) coverage in Myan-
mar is well below average. This study describes retention and
baseline predictors of prognosis from the largest ART program in
the country.
Methods: A cohort analysis of adult patients who initiated ART
during 2003–2007 was conducted, with follow-up until the end of
2009. The primary outcome was attrition [death plus losses to fol-
low-up (LTF)]. Baseline variables were assessed as potential risk
factors. The cumulative probabilities of death, LTF, and attrition
up to 5 years were described using Kaplan–Meier estimates. Cox
regression was used to calculate hazard ratios of attrition, overall and
separately for 2 time periods on ART: 1–6 and 7–36 months.
Results: A total of 5963 adults enrolled in the program, providing
17,581 person-years of follow-up. Median age at baseline was 33
years [interquartile range (IQR): 28–38], 61% were men, 45% were in
World Health Organization stage IV, and the median CD4 count was
71 cells per cubic millimeter (IQR: 29–164). There were 821 (13.8%)
deaths and 389 (6.5%) LTF over the study period, with a 72% prob-
ability of being retained in care in the 5-year cohort. Double the rate
of loss was contributed by death compared with LTF, and attrition
was almost 4 times higher in the period 1–6 months compared with
7–36 months. In the multivariable analyses of the program overall,
older age [adjusted hazard ratio (aHR): 1.56, 95% conﬁdence interval
(CI): 1.25 to 1.94], being male (aHR: 1.52, 95% CI: 1.25 to 1.85),
World Health Organization stage IV (aHR: 1.44, 95% CI: 1.19 to
1.74), and body mass index ,16 kg/m2 (aHR: 2.13, 95% CI: 1.71 to
2.66) were independently predictive of attrition.
Conclusions: The excellent retention over .6 years in this large
cohort demonstrates that ART delivery at the primary care level in
Myanmar is feasible and should encourage support for further ART
expansion in the country.
Key Words: antiretroviral treatment, HIV, predictors, risk factors,
prognosis, attrition, retention, mortality, primary care, resource lim-
ited, Asia, Myanmar, Burma, cohort
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INTRODUCTION
The Union of Myanmar is ranked 132 of 169 countries
on the Human Development Index and is the least developed
country in Southeast Asia.
1 Government expenditure on health
is 0.2% of total gross domestic product compared with 1.7%
in neighboring Cambodia,
1 which receives 10 times more ofﬁ-
cial development assistance ($US 46 per capita vs $US 4).
2
Formerly known as Burma, the country was renamed Myan-
mar in 1989. It has an estimated population of 50 million and
adult HIV prevalence of 0.6%.
3 HIV prevalence estimates in
“most-at-risk” groups in the capital city are the highest in the
South and Southeast Asia region (18% for female sex workers
and 29% for men who have sex with men). Over a third (38%)
of injection drug users are HIV positive.
3 There were an esti-
mated 17,000 new infections in 2009, second only to India in
the South/Southeast Asia region, and 18,000 AIDS-related
deaths.
3 Of the 120,000 people estimated to need antiretroviral
therapy (ART), 24% (29,825) received it in Myanmar com-
pared with 47% ART coverage overall for low-income and
middle-income countries (based on ART eligibility at CD4
count ,350 cells/mm3).
4 In 2010, 55% (n = 16,519) of all
reported ART provided in the country was supported by the
program in this study.
The beneﬁts of ART in resource-poor settings have
long been demonstrated,
5 and Médecins Sans Frontières
(MSF) began the ﬁrst ART program in Myanmar in 2003.
As an independent nongovernmental organization, MSF was
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pital, and from the outset all care has been provided at the
primary care level. In this article, we report outcomes from
the MSF program where antiretroviral treatment was provided
on a large scale from a primary care level over a period of
.6 years in Myanmar—an Asian severely resource-limited
setting where access to treatment is considerably outweighed
by the need
4 and resources for health are limited.
1,2
METHODS
Program Design and Care Provision
Patients accessed the clinics from all over the country
but were principally from Yangon, Kachin, Shan, and
Rakhine states (see Map, Supplemental Digital Content 1,
http://links.lww.com/QAI/A279). These were the 4 locations
where MSF worked based on unmet needs and government
permission to operate. All care was provided free of charge
across 10 main primary care and satellite sites. Clinical con-
sultations were performed by medical doctors, as is the case
in most Asian HIV treatment programs. In general, a multi-
disciplinary team composed of a speciﬁc doctor, nurse, coun-
selor, and outreach support worker managed a given patient,
providing continuity of care. The counselors and out-
reach support workers were lay people trained to perform
their roles and were often people living with HIV/AIDS them-
selves. Adherence support was provided by these coun-
selors in the clinic, and in the community by the outreach
support workers. The latter had both defaulter tracing and
defaulter prevention functions, and helped patients resolve
social problems and address adherence issues with the
clinic-based team. If patients had died in the community, this
was ascertained and reported when possible. In excep-
tional cases (eg, those with disabilities or debilitating factors),
patients were given ﬁnancial support for transport to attend
follow-up visits at the discretion of the multidisciplinary
team. Local food support was provided for the ﬁrst 6 months
on ART.
Routine follow-up after ART initiation was done at
2 weeks, 1 month, 2 months, 3 months, and 3 monthly
thereafter. Initially, access to CD4 count testing was limited
and ART was initiated based on World Health Organization
(WHO) clinical staging criteria alone (WHO stage III or IV)
as there was no access to reliable CD4 count testing. This
became available in 2005 but was still not routinely accessible
at the end of the study period at all sites. There was no access
to routine viral load monitoring in the country throughout the
study period.
All medications (antiretrovirals, treatment for opportu-
nistic infections, and cotrimoxazole prophylaxis) were pre-
scribed according to contemporaneous WHO guidelines
6–8
(national guidelines followed WHO guidelines). First-line
ART comprised nevirapine, stavudine (with efavirenz and
zidovudine, respectively, as alternatives when indicated),
and lamivudine; and second-line ART comprised a ritonavir
boosted protease inhibitor (lopinavir or saquinavir)–based reg-
imen. Opportunistic infection [including tuberculosis (TB)]
management was fully integrated with HIV care as a one-stop
service at all clinics. When indicated, intravenous infusions
were administered on site. Patients requiring hospitalization
were referred to the nearest Ministry of Health hospital. Dur-
ing hospitalization, MSF clinicians were no longer involved in
the clinical management of patients but ART supplies contin-
ued to be dispatched.
Data Management and Analysis
All adult patients ($15 years) who initiated combina-
tion ART between March 2003 (when the program started)
and July 2007 were included in the analysis and followed-up
until the end of 2009. Baseline characteristics were collected
by attending clinicians and entered into an Access database
(Fuchia version 1.4; Epicentre, Paris, France). The primary
outcome of interest was attrition, deﬁned as known deaths
plus losses to follow-up (LTF). This deﬁnition was used to
include patients who would have a poor prognosis, whether
due to death or not receiving further care. Rates for death and
LTF were also examined separately. We deﬁned LTF as an
absence of .60 days from last appointment, consistent with
empirically derived deﬁnitions.
9 Patients who transferred to
another site were censored. Retention refers to all patients
remaining in care (ie, after accounting for deaths, loss to
follow-up, and transfers).
The following baseline variables, determined by history
and clinical assessment by clinicians, were assessed as
potential risk factors for attrition: age group, sex, WHO
stage, body mass index (BMI), CD4 count, TB in the previous
5 years or at ART initiation, oral candidiasis and oral hairy
leukoplakia (WHO stage III–deﬁning conditions), prior ART
exposure (mainly prescribed by private practitioners or
bought in pharmacies), employment status, and year of ART
initiation. TB diagnosis was based on clinical screening,
microscopy (available at clinics), and chest x-ray (referred
to radiography centers). CD4 count was expected to be miss-
ing in the majority of patients due to limited access to testing
up to the end of the study period. Some sites had routine
access after 2005, and others used it when in doubt of eligi-
bility for ART or in exceptional cases. This variable was
examined as a risk factor, acknowledging the limitations in
terms of the generalizability of any associations found. Mul-
tiple imputation of missing CD4 counts and BMI values was
considered, but there were concerns that inaccurate results
could be obtained because it was not plausible to assume that
data were missing at random. For example, in all but 5
patients, missing BMI values were due to lack of data for
height. One reason for missing height data was that moribund
patients did not have their heights measured and therefore
patients with missing BMI data could be different to those
with available data in important ways that could affect the
outcome of interest. However, this was not the only reason,
and omission by clinical staff also occurred in this operational
setting. Thus, analyses that included BMI and CD4 count as
explanatory variables were restricted to individuals with data
on these variables.
The cumulative probability of death, LTF, and attrition
over time were described using Kaplan–Meier estimates.
Baseline characteristics were described using medians and
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counts and percentages for categorical variables. Univariable
Cox regression was used to assess rates of attrition, and of
death and LTF (data not shown). Multivariable Cox propor-
tional hazards models for attrition were built for each explan-
atory variable, assessing the other variables as potential
confounding factors, in a forward stepwise approach. The
ﬁnal multivariable models were limited to individuals with
available values for all explanatory variables and included
all variables except for CD4 count (n = 3879), with WHO
stage preferred as a measure of immune suppression because
data on it were available for almost all patients. The propor-
tional hazards assumption was assessed by examining hazard
ratios (HRs) over time using Nelson–Aalen plots and formally
with likelihood ratio tests. Changing rates over time were
examined with Lexis expansion of the data, and proportion-
ality assessed for the several time periods. Finally, further
analysis was done separately for the time intervals 1–6 and
7–36 months (still examining the association with baseline
characteristics) on the basis of observed period-speciﬁc HRs
and statistical tests for interaction, which showed evidence of
variation in rate ratios between, but not within, these 2 time
periods. The period beyond 3 years was not examined for risk
factors due to smaller numbers in the cohort beyond this time.
All analyses were performed using Stata version 11.0
for Windows (Stata Corp, College Station, TX). The study
was approved by the Ethics Committee of the London School
of Hygiene and Tropical Medicine. All patient information
was entered into the database using coded identiﬁcation
numbers, and no information that could reveal patient identity
was entered into the database.
RESULTS
Between 2003 and mid-2007, 5963 adults enrolled for
combination ART in the program (see Figure, Supplemental
Digital Content 2, http://links.lww.com/QAI/A280), with a
total of 17,581 person-years of follow-up over a period of
6.8 years and a median follow-up of 3 years (IQR: 2.4–3.8)
in the study. Seventy-six percent of patients were retained alive
at the end of the observation period, with 821 (13.8%) deaths,
389 (6.5%) LTF, and 210 (3.5%) transferred to other providers.
Median age at baseline was 33 years (IQR: 28–38) and
61% of patients were men. Forty-nine percent of patients
were classiﬁed as WHO stage III and 45% as WHO stage
IV at baseline. The proportion of patients with missing CD4
count values was the same whether individuals were in WHO
stage IV or not (56%). Among patients for whom CD4 count
was available (n = 2608), the median CD4 count was 71 cells
per cubic millimeter (IQR: 29–164) and 42% had a CD4
count #50 cells per cubic millimeter. Of 4078 (68%) patients
with BMI measurements, 54% (n = 2199) were underweight
and 18% (n = 748) were severely underweight (deﬁned
as ,18.5 and ,16 kg/m2, respectively, according to the
WHO cutoffs
10). Sixty-two percent of patients (n = 3721)
had a history of TB at baseline (39% had active TB when
initiating ART). A third of the cohort was unemployed when
initiated on ART (Table 2).
The cumulative probabilities of retention after losses
due to mortality, LTF, and attrition in the program over time
after starting ART are shown in Table 1 and Figure 1; Figure 2
displays these outcomes by year of ART initiation. Attrition
in the ﬁrst year on ART was 11%, and among those eligible
for 5 years of follow-up, 72% were still retained alive at this
time. During the ﬁrst 6 months, 499 attritions occurred over
2811 person-years at risk and the rate of attrition was 17.8/
100 person-years [95% conﬁdence interval (CI): 16.3 to
19.4]. This is almost 4 times higher than in the period 7–36
months, with 562 attritions over 12,043 person-years at risk
(4.7/100 person-years, 95% CI: 4.3 to 5.1). Double the rate
of attrition was contributed by death compared with LTF
(4.7 compared with 2.2/100 person-years) overall.
Risk factors for attrition in the program over 6.8 years
of follow-up included BMI ,16 kg/m2 (HR: 2.04, 95% CI:
1.66 to 2.51), WHO stage IV (HR: 1.62, 95% CI: 1.44 to
1.81), age $40 years (HR: 1.58, 95% CI: 1.36 to 1.83), and
being male (HR: 1.22, 95% CI: 1.08 to 1.37) (Table 2). After
adjusting for confounding factors, these associations persisted
(Table 2), but individuals with current or previous TB had
a lower rate of attrition [adjusted HR (aHR): 0.75, 95% CI:
0.62 to 0.92]. Multivariable analyses of attrition, and death
and LTF separately, show a very similar pattern of associa-
tions between the baseline characteristics and each of attrition
and death (data not shown). Most estimates for associations
with LTF did not reach statistical signiﬁcance, although being
unemployed was associated with lower LTF rates and age
$15–29.9 years was associated with 68% higher LTF
(aHR: 1.68, 95% CI: 1.17 to 2.42).
Examining the associations by time period on ART, the
strongest predictor of attrition (among those with complete
TABLE 1. Cumulative Probabilities of Retention Over Time on ART
Duration on ART Losses Due to Deaths and LTF* (95% CI) Losses Due to Deaths Only† (95% CI) Losses Due to LTF Only‡ (95% CI)
3 mo 0.94 (0.93 to 0.95) 0.95 (0.94 to 0.95) 1.00 (0.99 to 1.00)
6 mo 0.92 (0.91 to 0.92) 0.93 (0.92 to 0.93) 0.99 (0.99 to 0.99)
1 yr 0.89 (0.88 to 0.90) 0.91 (0.90 to 0.91) 0.98 (0.98 to 0.99)
3 yr 0.82 (0.81 to 0.83) 0.87 (0.86 to 0.87) 0.94 (0.93 to 0.95)
5 yr 0.72 (0.70 to 0.74) 0.83 (0.82 to 0.85) 0.86 (0.84 to 0.88)
The lower/upper 95% CI may be the same as some point estimates due to rounding to 2 decimal places.
*Transfers censored from analysis.
†LTF and transfers censored.
‡Deaths and transfers censored.
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n( % * )
Rate of Attrition†
Per 100 Person-Yr
(95% CI)
Univariable HR of
Attrition†
(95% CI) P‡
Multivariable
HR of Attrition†
(95% CI) P‡
Overall 5963 (100) 6.9 (6.5 to 7.3)
Sex
Female 3656 (61.3) 6.1 (5.5 to 6.7) 1 0.001 1 ,0.001
Male 2307 (38.7) 7.39 (6.9 to 7.9) 1.22 (1.08 to 1.37) 1.52 (1.25 to 1.85)
Age at ART initiation (yr)
$15–29.9 1786 (34.9) 6.7 (6.1 to 7.4) 0.94 (0.81 to 1.08) ,0.001 1.04 (0.85 to 1.27)
$30–39.9 2370 (46.4) 6.3 (5.7 to 7.0) 1 ,0.001§ 1 ,0.001
$40–79.9 957 (18.7) 10.6 (9.5 to 12.0) 1.58 (1.36 to 1.83) 1.56 (1.25 to 1.94)
Missing 850 (14.3) 4.7 (3.9 to 5.6) 0.64 (0.53 to 0.78)
WHO stage IV
No 3198 (54.0) 5.4 (4.9 to 5.8) 1 ,0.001 1 ,0.001
Yes 2740 (46.0) 8.7 (8.0 to 9.4) 1.62 (1.44 to 1.81) 1.44 (1.19 to 1.74)
Missing 25 (0.4) 18.8 (10.4 to 33.9) 2.17 (1.19 to 3.93) 0.02§
CD4 count (cells/mm3)
#50 1082 (41.5) 9.4 (8.4 to 10.6) 1 ,0.001 1 ,0.001
.51–100 540 (20.7) 5.3 (4.3 to 6.6) 0.57 (0.44 to 0.72) 0.65 (0.47 to 0.91)
.101–200 597 (22.9) 3.9 (3.0 to 4.9) 0.41 (0.31 to 0.53) 0.58 (0.41 to 0.82)
.201 389 (14.9) 3.8 (2.8 to 5.1) 0.40 (0.29 to 0.55) 0.55 (0.36 to 0.85)
Missing 3355 (56.3) 7.3 (6.8 to 7.8) 1.15 (1.03 to 1.29) 0.02§
BMI (kg/m2)
$18.5 1879 (46.1) 3.5 (3.0 to 4.0) 1 ,0.001 1 ,0.001
$16 to ,18.5 1451 (35.6) 4.0 (3.4 to 4.6) 1.15 (0.94 to 1.40) 1.17 (0.95 to 1.45)
,16 748 (18.3) 7.1 (6.0 to 8.2) 2.04 (1.66 to 2.51) 2.13 (1.71 to 2.66)
Missing 1885 (31.6) 14.1 (13.1 to 15.3) 3.31 (2.95 to 3.71) ,0.001§
Ever had TB
No 2242 (37.6) 6.4 (5.8 to 7.0) 1 0.05 1 0.005
Yes 3721 (62.4) 7.2 (6.7 to 7.7) 1.13 (1.00 to 1.27) 0.75 (0.62 to 0.92)
Oral candidiasis
No 3583 (60.1) 6.6 (6.1 to 7.1) 1 0.09 1 0.19
Yes 2380 (39.9) 7.3 (6.7 to 7.9) 1.10 (0.98 to 1.24) 1.13 (0.94 to 1.37)
Oral hairy leukoplakia
No 2921 (49.0) 7.2 (6.7 to 7.8) 1 0.09 1 0.18
Yes 3042 (51.0) 6.5 (6.0 to 7.1) 0.91 (0.81 to 1.02) 0.88 (0.73 to 1.06)
Prior ART exposure
No 5461 (91.6) 7.0 (6.6 to 7.4) 1 0.02 1 0.28
Yes 502 (8.4) 5.4 (4.4 to 6.8) 0.78 (0.62 to 0.97) 1.11 (0.92 to 1.35)
Unemployed
No 3849 (66.4) 6.2 (5.8 to 6.7) 1 ,0.001 1 0.30
Yes 1944 (33.6) 7.7 (7.0 to 8.4) 1.23 (1.10 to 1.39) 0.84 (0.62 to 1.17)
Missing 170 (2.9) 14.4 (11.1 to 18.6) 2.14 (1.64 to 2.80) ,0.001§
Year of ART start
2003 78 (1.3) 6.5 (4.4 to 9.7) 0.81 (0.53 to 1.23) 0.97 (0.57 to 1.65)
2004 384 (6.4) 6.3 (5.1 to 7.6) 0.78 (0.62 to 0.98) 0.43 (0.29 to 0.65)
2005 1380 (23.1) 7.0 (6.3 to 7.8) 0.87 (0.74 to 1.03) 0.62 (0.48 to 0.81)
2006 2741 (46.0) 6.4 (5.9 to 7.0) 0.80 (0.69 to 0.93) 0.59 (0.47 to 0.73)
2007 (up to July) 1380 (23.1) 8.1 (7.1 to 9.1) 1 0.06 1 ,0.001
*Percentage shown for available values are after excluding missing values; for missing values, percentages are as proportion of total.
†Univariable HRs were derived from Cox regression and therefore adjusted for time since ART initiation. Multivariable HRs are adjusted for all the other variables except for CD4
count (n = 3879), and the multivariable model for CD4 count is adjusted for all the other variables except for WHO stage (n = 2085) (see Methods). The multivariable models are
limited to individuals with available values for all explanatory variables. Limiting the univariable analyses to individuals with available values for all explanatory variables did not
change the conclusions drawn. When separate multivariable analyses were done adjusting for clinic site, the conclusions were the same (data not shown).
‡Likelihood ratio test.
§P value for the HR of attrition, comparing individuals with missing data with those with data available on the explanatory variable.
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,16 kg/m2, and the rate at which these individuals were lost
from the program was 4 times higher than those with normal
BMI (HR: 4.15, 95% CI: 2.93 to 5.91); and even those with
BMI $16 to ,18.5 kg/m2 had a 62% higher rate of attrition
(HR: 1.62, 95% CI: 1.11 to 2.34). After adjusting for con-
founding factors, the attrition rate associated with having
BMI ,16 kg/m2 remained considerable (aHR: 3.80, 95%
CI: 2.60 to 5.53) in this early period and was still predictive
of attrition among individuals surviving into the period 7–36
months after starting ART (aHR: 1.48, 95% CI: 1.06 to 2.07).
Men had a higher rate of attrition in both the time
periods (aHR: 1.29, 95% CI: 0.94 to 1.78 for 1–6 months;
aHR: 1.63, 95% CI: 1.23 to 2.15 for 7–36 months), and
individuals aged $40 years had a higher attrition rate com-
pared with those aged $30–39.9 years in both time periods
even after adjusting for confounding factors (aHR: 1.54, 95%
CI: 1.07 to 2.21 for 1–6 months; aHR: 1.76, 95% CI: 1.28 to
2.43 for 7–36 months). Being in WHO stage IV was also
associated with worse outcomes for both time periods and
remained a signiﬁcant risk factor for attrition in the multivari-
able analysis in the ﬁrst 6 months (aHR: 1.88, 95% CI: 1.35 to
2.61) but was less predictive after this period (aHR: 1.26,
95% CI: 0.95 to 1.66). Similarly, for patients with available
CD4 counts, this variable was strongly predictive of loss from
the program in the early period on ART but was not associ-
ated with worse prognosis after this (Table 3).
WHO stage and BMI were the most important con-
founding factors in the multivariable analyses. Patients with
missing values had worse attrition than those with available
values for all relevant explanatory variables except for
missing age category (Table 2).
DISCUSSION
This study describes outcomes on ART from a large
cohort (almost 6000 patients) over a substantial period of time
(6.8 years) and demonstrates the feasibility of obtaining
excellent outcomes (probability of retention 5 years after
starting ART was 72%) from a primary care setting in
Myanmar. Published data on simpliﬁed ART provision come
mainly from sub-Saharan Africa,
11–13 and Asian studies are
mainly from programs in middle-income countries and/or
providing hospital-linked care.
14–17 In contrast, little robust
independent data from Myanmar have been published to date.
A recent systematic review estimated retention in sub-
Saharan African programs of 72% at 3 years, and a network
of South African cohorts demonstrated retention of 56% at 5
years,
13,16 whereas in our study these probabilities were 82%
and 72%, at 3 and 5 years, respectively (Table 1). The out-
comes here are commendable even compared with other
established ART programs with international support.
12,18,19
The free provision of integrated “one-stop” care for HIV, TB,
and other opportunistic infections and also nutrition support
could be a key reason for the good outcomes seen in this
study. Additionally, this program had relatively highly trained
local clinical staff and a patient-centered approach to clinic
and community adherence support. The disproportionately
high rate of mortality-associated attrition in the early months
on treatment are well documented,
11,15,16,20,21 along with the
association with advanced disease by the time of presentation
for treatment,
12,19 which was also seen in our study. ART
scale-up was not associated with increases in attrition overall
in this program, unlike what has been seen elsewhere,
16,22 and
attrition rates differed little according to the calendar year in
which ART was initiated (Table 2). Over calendar time, we
did ﬁnd that death rates declined as clinical experience grew,
whereas LTF worsened (Fig. 1) possibly due to the increasing
cohort size, as has been reported by other studies.
22,23 Death
was the major contributor to attrition, with rates of LTF
accounting for less than a third of the overall attrition rate.
This is similar to what was seen in a study from Cambodia
15
but is in contrast to what is reported in ART programs in
sub-Saharan Africa, where LTF was the dominant contributor
to attrition.
13,16 This program had an intensive community
adherence, defaulter prevention, and tracing component,
which could have minimized LTF and supported the accurate
ascertainment of deaths and transfers.
The proportion of patients with low BMI (18% ,16 kg/m2
or 54% ,18.5 kg/m2) and WHO stage IV (46%) indicates
the advanced condition of the patients presenting for HIV and
ART care. The median value for those with access to CD4
count was 71 cells per cubic millimeter, which is much lower
than the median count reported for Asian Antiretroviral Therapy
in Lower Income Countries cohorts (123 cells/mm3).
24
Most risk factors were strongly predictive of attrition in
the ﬁrst 6 months, but this waned over time. Older patients
($40–79.9 years), comprising almost a ﬁfth of the cohort
overall (19%), were identiﬁed to be at higher risk of poor
FIGURE 1. Cumulative probabilities of retention on ART in the
program overall with LTF, death, and attrition (death + LTF) as
failure outcomes.
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not explained by markers of disease severity and alludes to
the complex interplay of HIV and aging.
25 We also identiﬁed
men as being at higher risk of attrition; given that the majority
of HIV-infected adults in Myanmar are male
26 (and comprise
61% in this cohort), they are an important target group for
earlier diagnosis and recruitment into HIV treatment
programs.
Sixty-two percent of patients had a history of TB
diagnosis at the time of ART initiation (either diagnosed and
treated before presenting for ART care or concurrent with
ART initiation), and this highlights the fact that HIV–TB
coinfection is common in this setting, which is a recognized
high TB prevalence country.
27 The worse attrition associated
with having TB was explained by WHO staging and BMI,
and after adjusting for these factors, it was associated with
reduced attrition. The reason for this is probably complex. For
example, the majority of patients who had a history of TB
were on TB treatment when starting ART and had lower LTF
(data not shown) and their lower attrition rate may be due to
enhanced adherence while on TB treatment, whereas patients
with previous TB had already survived this before starting
ART and thus may have had other survival advantages (eg,
better prepared for adhering to treatment).
BMI category in this cohort turned out to be the
strongest independent predictor of attrition from the ART
program. This is an ominous ﬁnding, given that almost a ﬁfth
(18%) of those with BMI measurements had a BMI of
,16 kg/m2 in this cohort and is relevant for countries where
both food insecurity and HIV are important public health
FIGURE 2. Cumulative probabilities of retention on ART with LTF, death, and attrition (death + LTF) as failure outcomes, by year
of ART initiation.
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e58 | www.jaids.com  2012 Lippincott Williams & WilkinsTABLE 3. Hazard Ratios of Attrition (Death + LTF) After 1–6 and 7–36 Months on ART
Baseline Characteristics
(excluding missing values)
7–36 Months
Rate of Attrition*
(per 100 py) (95% CI) Univariable HR* (95% CI) P† Multivariable HR (95% CI)* P†
Overall 17.8 (16.3 to 19.4)
Sex
Female 14.9 (12.8 to 17.3) 1 0.004 1 1
Male 19.6 (17.6 to 21.8) 1.31 (1.09 to 1.59) 1.29 (0.94 to 1.78) 0.1
Age at ART start (yr)
$15–29.9 18.2 (15.6 to 21.4) 0.94 (0.77 to 1.16) 0.91 (0.65 to 1.28)
$30–39.9 19.4 (16.9 to 22.1) 1 0.02 1 0.06
$40–79.9 25.6 (21.3 to 30.8) 1.32 (1.05 to 1.66) 1.54 (1.07 to 2.21)
Missing 4.3 (2.7 to 6.8) 0.22 (0.14 to 0.35) 0.001‡
WHO stage IV
No 10.3 (8.8 to 12.0) 1 0.001 1 ,0.001
Yes 26.7 (24.0 to 29.7) 2.57 (2.13 to 3.11) 1.88 (1.35 to 2.61)
Missing 46.4 (19.3 to 111.6) 1.72 (0.71 to 4.15) 0.27‡
CD4 count (cells/mm3)
#50 35.6 (30.6 to 41.3) 1 ,0.001 1 ,0.001
.51–100 14.7 (10.7 to 20.2) 0.42 (0.29 to 0.59) 0.51 (0.31 to 0.84)
.101–200 5.8 (3.6 to 9.3) 0.17 (0.10 to 0.27) 0.26 (0.13 to 0.51)
.201 4.7 (2.5 to 9.1) 0.14 (0.07 to 0.26) 0.29 (0.13 to 0.64)
Missing 16.6 (14.7 to 18.7) 0.86 (0.72 to 1.03) 0.10‡
BMI (kg/m2)
$18.5 5.5 (4.2 to 7.3) 1 0.001 1 ,0.001
$16 to ,18.5 8.9 (7.0 to 11.5) 1.62 (1.11 to 2.34) 1.55 (1.05 to 2.28)
,16 23.1 (18.6 to 28.8) 4.15 (2.93 to 5.91) 3.80 (2.60 to 5.53)
Missing 36.4 (32.5 to 40.7) 3.64 (3.04 to 4.36) 0.001‡
Ever had TB ,0.001 0.13
No 13.9 (11.9 to 16.4) 1 1
Yes 20.1 (18.1 to 22.3) 1.44 (1.19 to 1.74) 0.76 (0.53 to 1.09)
Oral candidiasis
No 13.8 (12.2 to 15.7) 1 ,0.001 1 0.06
Yes 23.9 (21.1 to 26.9) 1.72 (1.44 to 2.05) 1.30 (0.95 to 1.78)
Oral hairy leukoplakia
No 18.2 (16.1 to 20.6) 1 0.60 1 0.63
Yes 17.3 (15.3 to 19.6) 0.95 (0.80 to 1.14) 0.87 (0.63 to 1.19)
Prior ART exposure
No 18.1 (16.5 to 19.8) 1 0.17 1 0.28
Yes 14.3 (10.2 to 19.9) 0.79 (0.56 to 1.12) 0.68 (0.38 to 1.23)
Unemployed
No 16.1 (14.4 to 18.1) 1 0.09 1 0.97
Yes 19.0 (16.4 to 22.1) 1.1 (0.98 to 1.42) 0.96 (0.69 to 1.32)
Missing 42.1 (29.6 to 59.9) 2.43 (1.69 to 3.50) ,0.001‡
Year of ART start
2003 24.7 (12.8 to 47.4) 1.79 (0.90 to 3.56) 1.38 (0.57 to 3.33)
2004 28.8 (21.8 to 38.0) 2.09 (1.48 to 2.96) 0.57 (0.29 to 1.11)
2005 21.3 (18.0 to 25.2) 1.56 (1.19 to 2.03) 0.73 (0.47 to 1.11)
2006 16.4 (14.4 to 18.8) 1.21 (0.94 to 1.54) 0.58 (0.40 to 0.83)
2007 (up to July) 13.6 (11.1 to 16.8) 1 0.001 1 0.02
(continued on next page)
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 2012 Lippincott Williams & Wilkins www.jaids.com | e59TABLE 3. (Continued) Hazard Ratios of Attrition (Death + LTF) After 1–6 and 7–36 Months on ART
Baseline Characteristics
(excluding missing values)
7–36 Months
Rate of Attrition*
(per 100 py) (95% CI) Univariable HR* (95% CI) P† Multivariable HR (95% CI)* P†
Overall 4.7 (4.3 to 5.1)
Sex
Female 4.3 (3.7 to 4.9) 1 0.09 1 ,0.001
Male 4.9 (4.4 to 5.5) 1.16 (0.97 to 1.38) 1.63 (1.23 to 2.15)
Age at ART start (yr)
$15–29.9 4.2 (3.6 to 4.9) 0.95 (0.77 to 1.17) 1.08 (0.80 to 1.46)
$30–39.9 4.4 (3.8 to 5.0) 1 ,0.001 1 0.007
$40–79.9 7.9 (6.7 to 9.3) 1.78 (1.44 to 2.21) 1.76 (1.28 to 2.43)
Missing 3.21 (2.5 to 4.2) 0.65 (0.50 to 0.86) 0.001‡
WHO stage IV
No 4.3 (3.8 to 4.8) 1 0.04 1 0.06
Yes 5.1 (4.5 to 5.8) 1.20 (1.01 to 1.41) 1.26 (0.95 to 1.66)
Missing 11.0 (4.1 to 29.3) 2.10 (0.78 to 5.65) 0.18‡
CD4 count (cells/mm3)
#50 4.3 (3.5 to 5.3) 1 0.65 1 0.89
.51–100 3.6 (2.7 to 4.9) 0.84 (0.58 to 1.22) 0.86 (0.54 to 1.37)
.101–200 3.5 (2.6 to 4.7) 0.82 (0.58 to 1.18) 0.95 (0.60 to 1.50)
.201 3.6 (2.5 to 5.1) 0.84 (0.55 to 1.27) 0.84 (0.47 to 1.48)
Missing 5.3 (4.8 to 5.9) 1.38 (1.17 to 1.65) ,0.001‡
BMI (kg/m2)
$18.5 2.9 (2.4 to 3.4) 1 0.10 1 0.05
$16 to ,18.5 3.0 (2.4 to 3.6) 1.02 (0.78 to 1.33) 0.99 (0.73 to 1.34)
,16 4.0 (3.1 to 5.2) 1.39 (1.02 to 1.89) 1.48 (1.06 to 2.07)
Missing 9.1 (8.1 to 10.2) 2.94 (2.49 to 3.47) ,0.001‡
Ever had TB 1 0.94
No 4.6 (4.1 to 5.3) 1 1 0.14
Yes 4.6 (4.2 to 5.2) 0.01 (0.85 to 1.19) 0.80 (0.60 to 1.08)
Oral candidiasis
No 4.9 (4.5 to 5.5) 1 0.07 1 0.65
Yes 4.2 (3.7 to 4.9) 0.86 (0.72 to 1.02) 1.10 (0.84 to 1.45)
Oral hairy leukoplakia
No 4.9 (4.4 to 5.5) 1 0.07 1 0.68
Yes 4.4 (3.9 to 5.0) 0.90 (0.76 to 1.06) 0.94 (0.72 to 1.25)
Prior ART exposure
No 4.8 (4.4 to 5.2) 1 0.08 1 0.44
Yes 3.6 (2.6 to 4.9) 0.75 (0.54 to 1.05) 0.81 (0.51 to 1.29)
Unemployed
No 4.3 (3.8 to 4.7) 1 0.02 1 0.11
Yes 5.3 (4.6 to 6.0) 1.23 (1.04 to 1.47) 1.34 (1.02 to 1.76)
Missing 7.9 (5.2 to 12.0) 1.72 (1.13 to 2.64) 0.02‡
Year of ART start
2003 4.4 (2.1 to 9.2) 0.65 (0.31 to 1.38) 1.00 (0.43 to 2.39)
2004 3.2 (2.2 to 4.7) 0.47 (0.31 to 0.73) 0.40 (0.20 to 0.79)
2005 4.5 (3.8 to 5.4) 0.67 (0.53 to 0.85) 0.66 (0.45 to 0.97)
2006 4.2 (3.7 to 4.7) 0.62 (0.51 to 0.75) 0.57 (0.42 to 0.79)
2007 (up to July) 6.5 (5.6 to 7.6) 1 0.001 1 0.002
*Univariable HRs were derived from Cox regression and therefore adjusted for time since ART initiation. Multivariable HRs are adjusted for all the other variables except for CD4
count (n = 3879), and the multivariable model for CD4 count is adjusted for all the other variables except for WHO stage (n = 2085) (see Methods). The multivariable models are
limited to individuals with available values for all explanatory variables. Limiting the univariable analyses to individuals with available values for all explanatory variables did not
change the conclusions drawn. When separate multivariable analyses were done adjusting for clinic site, the conclusions were the same (data not shown).
†Likelihood ratio test.
‡P value for the HR of attrition, comparing individuals with missing data with those with data available on the explanatory variable.
py, person-years.
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WHO stage IV at the time of starting ART was not predictive
of attrition in the 7- to 36-month period. It is most likely
explained by the fact that those with the worst condition died
early. However, it is also encouraging that with immune
reconstitution on ART, the extent of severity of baseline con-
dition mattered less over time.
Strengths of this study include the large cohort size and
long duration of follow-up, which allowed for precise
estimates to be reported over a long time frame. The
predictors of prognosis we identiﬁed add to the existing body
of evidence from a setting from which few published data are
available. As an observational study, this study had inherent
unmeasured risk factors, and thus, confounding effects and
the high proportion of missing data on baseline variables
(such as BMI and CD4 count) are a common problem for
operational cohorts.
24
The potential for misclassiﬁcation of mortality as loss to
follow-up is an important consideration that has been
highlighted by a recent systematic review that found that
when tracing studies were done, 20%–60% of patients lost to
follow-up have died.
28 In Myanmar, patients who are lost to
follow-up are unlikely to receive further care, given that
access to treatment in the country is relatively low and they
will have a poor prognosis without continued treatment. LTF
could also represent misclassiﬁcation of deaths that have
already occurred
22,29,30 and was regarded as a marker of poor
prognosis to avoid overestimating success in the program.
This study therefore examined attrition as the primary out-
come of interest taking a worst-case scenario approach. When
only known mortality was measured as an outcome instead,
the baseline characteristics were found to have similar asso-
ciations as seen with attrition (with the exception of year
of ART initiation, as described previously). This afﬁrmed
the choice of attrition as the outcome of interest for this
particular study and is backed by evidence suggesting an
inverse relationship between proportion of LTF overall and
the proportion of deaths among those classiﬁed as lost to
follow-up.
28 There is also evidence to suggest that the relative
contribution of death and LTF to overall attrition may diverge
over time.
23 Methods that have been proposed to estimate
true deaths out of those LTF were considered but were not
applied in this study because they are not applicable for data
beyond 12 months after starting ART.
31 Finally, the contri-
bution of an external organization is likely to have been an
important part of the program’s success. However, it is
important to note that the vast majority of clinical care is
provided by local clinical staff and with sufﬁcient government
prioritization and donor support, the services supported by
MSF could be more widely sustainable in the future.
Additional research on social and demographic factors
that may explain the low rates of LTF seen in this setting
would be illuminating. The routine clinical data used in this
study did not include extensive information on lifestyle
factors or on potential risk factors such as sex work, homo-
sexuality, or injecting drug use to avoid potential stigmatiza-
tion. It is known, however, that much of the cohort had a
history of 1 or more of these risk factors. An examination of
risk factors updated after periods of time on ART and their
associations with subsequent outcome would also be valuable
in guiding practice.
HIV prevalence in Myanmar is the second highest in
South/Southeast Asia (after Thailand), and the plight of those
who are HIV infected in Myanmar is dire, as evidenced by the
high proportion of patients with advanced disease at baseline of
treatment initiation and the low national ART coverage.
1 The
need for greater investments to support HIV/AIDS service pro-
vision in Asia has been highlighted.
32–34 The ﬁndings from this
study show that ART delivery in Myanmar is feasible and
a key policy implication should be for increased support for
ART expansion in one of the worst affected countries in the
region. The favorable treatment outcomes also demonstrate that
delivery of ART and integrated HIV management at primary
care level is a means to expand access to treatment not only in
Myanmar but also in other Asian resource-limited settings.
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